NovoMix 30 FlexPen 100 U/ml suspension for injection in a pre-filled pen

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

NovoMix 30 FlexPen 100 units/ml injection suspension in a pre-filled pen

30% soluble insulin aspart and 70% insulin aspart crystallized with protamine

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any questions, ask your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
• If you experience any side effects, talk to your doctor, pharmacist or nurse, even if they are side effects not listed in this leaflet. See section 4.

Contents of this leaflet

1. What NovoMix 30 is and what it is used for
2. What you need to know before you use NovoMix 30
3. How to use NovoMix 30
4. Possible side effects
5. How to store NovoMix 30
6. Contents of the pack and other information

1. What NovoMix 30 is and what it is used for

NovoMix 30 is a modern (insulin analogue) with rapid- and intermediate-acting components in a 30/70 ratio. Modern insulins are improved versions of human insulin.

NovoMix 30 is used to lower high blood glucose levels in adults, adolescents, and children aged 10 years and older with diabetes mellitus (diabetes). Diabetes is a condition in which your body does not produce enough insulin to control your blood glucose level.

NovoMix 30 begins to lower your blood glucose level approximately 10 – 20 minutes after injection, reaches maximum effect between 1 and 4 hours after injection, and its effect lasts up to 24 hours.

In patients with type 2 diabetes mellitus, NovoMix 30 can be used in combination with oral antidiabetic tablets and/or injectable antidiabetic medicines.

2. What you need to know before using NovoMix 30

Do not use NovoMix 30

• If you are allergic to insulin aspart or to any of the other ingredients of this medicine (see section 6, Package contents and other information).
• If you suspect you are beginning to experience hypoglycaemia (low blood sugar levels), see a) Summary of serious and very common adverse effects in section 4.
• In insulin infusion pumps.
• If your FlexPen has been dropped, damaged, or broken.
• If it has not been stored correctly or if it has been frozen, see section 5, Storage of NovoMix 30.
• If the insulin does not appear uniformly white, cloudy, and watery when resuspended.
• If, after resuspension, it contains clumps or there are white solid particles adhering to the bottom or sides of the cartridge.

If any of these situations apply, do not use NovoMix 30. Consult your doctor, nurse, or pharmacist.

Before using NovoMix 30

• Check the label to make sure it is the correct type of insulin.
• Always use a new needle for each injection to avoid contamination.
• You must not share needles or your NovoMix 30 FlexPen.
• NovoMix 30 FlexPen is intended only for subcutaneous injection. Consult your doctor if you need to administer insulin by another method.

Warnings and precautions

Certain conditions and activities may affect your need for insulin. Consult your doctor:

• If you have kidney, liver, adrenal, pituitary, or thyroid gland problems.
• If you are doing more physical exercise than usual or if you wish to change your usual diet, as this may affect your blood sugar levels.
• If you are ill, continue using your insulin and consult your doctor.
• If you are travelling abroad, travelling across different time zones may affect your insulin requirements and the timing of administration.

Skin changes at the injection site

You should rotate your injection site to help prevent changes in fatty tissue, such as thickening of the skin, skin shrinkage, or lumps under the skin. Insulin may not work as well if injected into an area that is lumpy, shrunken, or thickened (see section 3, How to use NovoMix 30). Inform your doctor if you notice any changes at the injection site. Inform your doctor if you are currently injecting into these affected areas before switching to a different site. Your doctor may advise you to monitor your blood sugar levels more closely and may adjust your insulin dose or the dose of your other antidiabetic medications.

Children and adolescents

• NovoMix 30 can be used in adolescents and children aged 10 years and older.
• There is limited experience with NovoMix 30 in children aged 6 to 9 years.
• No data are available for NovoMix 30 in children under 6 years of age.

Other medicines and NovoMix 30

Inform your doctor, nurse, or pharmacist if you are taking, have recently taken, or might need to take any other medicines. Some medicines affect your blood sugar levels, which may require adjustment of your insulin dose. The main medicines that may affect your insulin treatment are listed below.

Your blood sugar level may decrease (hypoglycaemia) if you take:

• Other medicines for the treatment of diabetes
• Monoamine oxidase inhibitors (MAOIs) (used to treat depression)
• Beta-blockers (used to treat high blood pressure)
• Angiotensin-converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)
• Salicylates (used to relieve pain and reduce fever)
• Anabolic steroids (such as testosterone)
• Sulphonamides (used to treat infections)

Your blood sugar level may increase (hyperglycaemia) if you take:

• Oral contraceptives (birth control pills)
• Thiazides (used to treat high blood pressure or excessive fluid retention)
• Glucocorticoids (such as “cortisone” used to treat inflammation)
• Thyroid hormones (used to treat thyroid gland disorders)
• Sympathomimetics (such as epinephrine [adrenaline], salbutamol, or terbutaline used to treat asthma)
• Growth hormone (a medicine to stimulate somatic and skeletal growth that strongly influences metabolic processes)
• Danazol (a medicine that affects ovulation)

Octreotide and lanreotide (used to treat acromegaly, a rare hormonal disorder usually occurring in middle-aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar levels.

Beta-blockers (used to treat high blood pressure) may weaken or completely suppress the early warning symptoms that help you recognize when your blood sugar level is low.

Pioglitazone (tablets used to treat type 2 diabetes)

Some patients with long-standing type 2 diabetes and heart disease or prior stroke who were treated with pioglitazone and insulin developed heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath, rapid weight gain, or localized swelling (oedema).

If you have taken any of the medicines listed above, inform your doctor, nurse, or pharmacist.

Alcohol and use of NovoMix 30

• If you drink alcohol, your insulin requirement may change, as your blood sugar level may increase or decrease. Careful monitoring is recommended.

Pregnancy and breastfeeding

• If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine. Clinical experience with insulin aspart during pregnancy is limited. Your insulin dose may need to be adjusted during pregnancy and after delivery. Careful control of your diabetes is important for your baby’s health, especially to prevent hypoglycaemia.
• There are no restrictions on treatment with NovoMix 30 during breastfeeding.

Consult your doctor, pharmacist, or nurse before using any medicine during pregnancy or breastfeeding.

Driving and use of machines

• Please ask your doctor whether you may drive or operate machinery:
• If you frequently experience hypoglycaemia.
• If you have difficulty recognizing hypoglycaemia.

If your blood sugar levels are low or high, they may affect your concentration and reaction ability, and therefore also your ability to drive or operate machinery. Be aware that you could endanger your life or the lives of others.

Important information about some of the ingredients of NovoMix 30

NovoMix 30 contains less than 1 mmol (23 mg) of sodium per dose and is therefore essentially considered “sodium-free.”

3. How to use NovoMix 30

Dosage and when to administer insulin

Always use insulin and adjust the dose exactly as your doctor has recommended. If in doubt, consult your doctor, pharmacist, or nurse again.

NovoMix 30 is usually administered immediately before a meal. Eat a meal within 10 minutes after injection to avoid a drop in blood sugar. If necessary, NovoMix 30 may be administered shortly after a meal. For more information, see below under How and where to inject.

Do not switch insulin unless your doctor tells you to do so. If your doctor switches you to another type or brand of insulin, you may need a dosage adjustment.

When NovoMix 30 is used in combination with diabetes tablets and/or injectable antidiabetic medicines, your doctor may need to adjust your insulin dose.

Use in children and adolescents

NovoMix 30 can be used in adolescents and children aged 10 years and older when an insulin premix is preferred. Limited clinical data are available for children aged 6–9 years. No data are available for NovoMix 30 in children under 6 years of age.

Use in special patient groups

If you have impaired kidney or liver function (renal or hepatic insufficiency), or if you are over 65 years of age, you should monitor your blood sugar levels more frequently and discuss any changes in insulin dosage with your doctor.

How and where to inject

NovoMix 30 is injected under the skin (subcutaneous administration). Insulin must never be injected directly into a vein (intravenous administration) or into muscle (intramuscular administration). NovoMix 30 FlexPen is intended only for subcutaneous injection. Consult your doctor if you need to administer insulin by another method.

With each injection, rotate the injection site within the specific skin area you usually use. This may reduce the risk of developing lumps or pits in the skin (see section 4, Possible side effects). The best areas for injection are: the front of the waist (abdomen), the buttocks, the front of the thigh, or the upper arm. Insulin will act more quickly if injected into the abdominal area. You must always measure your blood sugar levels regularly.

How to use NovoMix 30 FlexPen

NovoMix 30 FlexPen is a disposable, pre-filled pen with a color code containing a mixture of fast-acting and intermediate-acting insulin aspart in a 30/70 ratio.

Read carefully the instructions for use included in this leaflet. You must use the pen exactly as described in the instructions for use.

Always make sure you are using the correct pen before injecting insulin.

If you use more insulin than you should

If you use too much insulin, your blood sugar level may become very low (hypoglycaemia). See a) Summary of serious and very common adverse effects in section 4.

If you forget to use your insulin

If you forget to use your insulin, your blood sugar level may become very high (hyperglycaemia). See c) Effects of diabetes in section 4.

If you stop using your insulin

Do not stop using your insulin without consulting your doctor first; your doctor will advise you what to do. Stopping treatment may result in very high blood sugar levels (severe hyperglycaemia) and ketoacidosis. See c) Effects of diabetes in section 4.

If you have any further questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

• Summary of serious and very common adverse effects

Low blood sugar (hypoglycaemia) is a very common adverse effect. It may affect more than 1 in 10 people.

Low blood sugar levels may occur if:

• You inject too much insulin.
• You eat too little or skip a meal.
• You exercise more than usual.
• You drink alcohol (see Alcohol and use of NovoMix 30 in section 2).

Symptoms of low blood sugar: Cold sweat, cold and pale skin, headache, palpitations, nausea, excessive hunger, temporary changes in vision, drowsiness, unusual tiredness and weakness, nervousness or trembling, feeling anxious, confusion, difficulty concentrating.

Severe hypoglycaemia can cause you to faint. If severe and prolonged hypoglycaemia is not treated, it may lead to brain injury (transient or permanent) and even death. Recovery of consciousness may be achieved more quickly with an injection of the hormone glucagon administered by someone trained to do so. If glucagon is administered, you should take glucose or sugary food as soon as you regain consciousness. If there is no response to glucagon treatment, you must be taken to hospital.

What to do if your blood sugar level is low:

• If your blood sugar level is low, take glucose tablets or a sugary food (e.g. sweets, biscuits, fruit juice). Check your blood sugar if possible and rest. Always carry glucose tablets or sugary food with you, just in case.
• Once symptoms of hypoglycaemia have disappeared or your blood sugar level has stabilized, continue your insulin treatment as usual.
• If you have had such a low blood sugar level that you fainted, if you required a glucagon injection, or if you have had multiple episodes of low blood sugar, speak to your doctor. It may be necessary to adjust your insulin dose or frequency, your diet, or your level of physical activity.

Inform others that you are diabetic and explain the possible consequences, including the risk of fainting (loss of consciousness) due to low blood sugar levels. Let them know that if you faint, they should lay you on your side and seek immediate medical help. They should not give you any food or drink as you could choke.

Serious allergic reactions to NovoMix 30 or one of its components (called a systemic allergic reaction) are very rare but potentially life-threatening adverse effects. It may affect up to 1 in 10,000 people.

Contact your doctor immediately:

• If allergy symptoms spread to other parts of your body.
• If you suddenly feel unwell: you sweat, feel nauseous (vomiting), have difficulty breathing, palpitations, or feel dizzy.
• If you experience any of these symptoms, contact your doctor immediately.

Skin changes at the injection site: If you inject insulin in the same place repeatedly, fatty tissue may shrink (lipoatrophy) or become thicker (lipohypertrophy) (may affect up to 1 in 100 people). Lumps under the skin may also occur due to accumulation of a protein called amyloid (cutaneous amyloidosis; frequency unknown). Insulin may not work well if injected into a lumpy, shrunken, or thickened area. Rotate your injection sites to help prevent these skin changes.

b) List of other adverse effects

Uncommon adverse effects

May affect up to 1 in 100 people.

Allergic symptoms: Local allergic reactions (pain, redness, hives, swelling, bruising, swelling, and itching) may occur at the injection site. These usually disappear after a few weeks of treatment. If symptoms do not resolve, you should consult your doctor.

Vision problems: When starting insulin treatment, you may experience vision problems, but this disturbance is usually temporary.

Joint swelling: When starting insulin treatment, fluid retention may cause swelling of the ankles and other joints. This effect usually disappears quickly. If not, consult your doctor.

Diabetic retinopathy (an eye disease related to diabetes that may lead to vision loss): If you have diabetic retinopathy and your blood sugar level improves very rapidly, the retinopathy may worsen. Consult your doctor.

Rare adverse effects

May affect up to 1 in 1,000 people.

Painful neuropathy (pain due to nerve damage): If your blood sugar level improves very rapidly, you may experience nerve-related pain. This is called acute painful neuropathy and is usually transient.

Reporting of adverse effects

If you experience any adverse effect, talk to your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: www.notificaRAM.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

c) Effects of diabetes

High blood sugar (hyperglycaemia)

High blood sugar levels may occur if:

• You have not injected enough insulin.
• You forget to inject your insulin or interrupt your insulin treatment.
• You repeatedly inject less insulin than you need.
• You have an infection and/or fever.
• You eat more than usual.
• You exercise less than usual.

Warning signs of high blood sugar:

Warning symptoms develop gradually. These include: increased need to urinate, thirst, loss of appetite, feeling dizzy (nausea or vomiting), drowsiness or tiredness, dry and flushed skin, dry mouth, and fruity-smelling breath (acetone).

What to do if your blood sugar level is high:

• If you notice any of the symptoms described: check your blood sugar level, check for ketones in your urine if possible, and contact your doctor immediately.
• These may be symptoms of a very serious condition called diabetic ketoacidosis (acid builds up in the blood because the body breaks down fat instead of sugar). If untreated, this could lead to diabetic coma and death.

5. Storage of NovoMix 30

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging and on the FlexPen label, after EXP. The expiry date refers to the last day of the month indicated.

Always keep the cap on the FlexPen when not in use, to protect it from light. NovoMix 30 must be protected from heat and excessive light.

Before opening: Unused NovoMix 30 FlexPen must be stored in the refrigerator between 2°C and 8°C, away from the cooling element. Do not freeze.

Before using NovoMix 30 FlexPen, remove it from the refrigerator. It is recommended to resuspend the insulin as instructed each time you use a new pen. See instructions for use.

During use or when carried as a spare: NovoMix 30 FlexPen in use or carried as a spare must not be stored in the refrigerator. It may be carried with you and stored at room temperature (below 30°C) for up to 4 weeks.

Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of NovoMix 30

• The active substance is insulin aspart. NovoMix 30 is a mixture consisting of 30% soluble insulin aspart and 70% insulin aspart crystallized with protamine. 1 ml contains 100 units of insulin aspart. Each pre-filled pen contains 300 units of insulin aspart in 3 ml of injectable suspension.
• The other components are glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, protamine sulfate, hydrochloric acid, sodium hydroxide and water for injections.

Appearance of NovoMix 30 and contents of the pack

NovoMix 30 is presented as a suspension for injection in a pre-filled pen. The cartridge contains a glass ball to aid resuspension. After resuspension, the liquid should have a uniformly white, cloudy and aqueous appearance. Do not use the pen if the resuspended insulin does not appear uniformly white, cloudy and aqueous.

Pack sizes of 1 (with or without needles), 5 (without needles) and 10 (without needles) pre-filled pens of 3 ml. Not all pack sizes may be marketed.

The suspension is cloudy, white and aqueous.

Marketing Authorisation Holder

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd, Denmark

Manufacturer

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd, Denmark

Novo Nordisk Production SAS
45, Avenue d’Orléans
F-28000 Chartres
France

Detailed instructions on how to use your FlexPen are printed on the reverse.

Date of the most recent revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the website of the European Medicines Agency: http://www.ema.europa.eu.

Instructions for use of NovoMix 30 injectable suspension in FlexPen.

Read the following instructions carefully before using your FlexPen. If you do not follow the instructions carefully, you may inject too little or too much insulin, which could result in blood sugar levels that are too high or too low.

FlexPen is a pre-filled insulin dosing pen.

• Doses from 1 to 60 units can be selected in increments of 1 unit.
• FlexPen is designed to be used with NovoFine or NovoTwist disposable needles of a length up to 8 mm.
• Always keep a spare insulin delivery device in case your FlexPen is lost or damaged.

Care of the pen

• You should handle your FlexPen with care. If it is dropped, damaged or subjected to strong impact, insulin may be lost. This could lead to inaccurate dosing, which may result in blood sugar levels that are too high or too low.

• You may clean the outside of your FlexPen with an alcohol-impregnated cotton pad. Do not immerse, wash or lubricate the pen, as it may be damaged.

• Do not refill your FlexPen.

Resuspension of insulin

A

Check the name and colour of the label on your pen to ensure it contains the correct type of insulin. This is especially important if you use more than one type of insulin. If you use the wrong type of insulin, your blood sugar level may become too high or too low.

Each time you use a new pen

Allow the insulin to reach room temperature before use. This makes resuspension easier.

Remove the cap from the pen.

B

Before administering the first injection with a new FlexPen, you must resuspend the insulin:

Roll the pen gently between the palms of your hands 10 times, making sure the pen remains in a horizontal position (parallel to the ground).

C

Move the pen up and down 10 times between the two positions shown in the illustration, ensuring the glass ball moves from one end of the cartridge to the other.

Repeat both movements until the liquid appears uniformly white, cloudy and aqueous.

For each subsequent injection

Move the pen up and down between the two positions at least 10 times until the liquid appears uniformly white, cloudy and aqueous.

• Always make sure you have resuspended the insulin before each injection. This reduces the risk of blood sugar levels becoming too high or too low. After resuspending the insulin, complete the following injection steps without delay.

Always check that at least 12 units of insulin remain in the cartridge to allow for proper resuspension. If less than 12 units remain, use a new FlexPen. The remaining insulin scale can be used to check whether 12 units remain. See the large illustration at the beginning of these instructions.

Do not use the pen if the resuspended insulin does not appear uniformly white, cloudy and aqueous.

Attaching the needle

D

Take a new needle and remove the paper tab.

Screw the needle straight and firmly onto your FlexPen.

E

Remove the large outer needle cap and keep it for later use.

F

Remove the inner needle cap and discard it.

Never try to reinsert the inner needle cap. You could prick yourself with the needle.

Always use a new needle for each injection. This reduces the risk of contamination, infection, insulin leakage, blocked needles and inaccurate dosing.

Be careful not to bend or damage the needle before use.

Checking insulin flow

Small amounts of air may accumulate in the cartridge during normal use before each injection. To avoid injecting air and to ensure proper dosing:

G

Turn the dose selector to select 2 units.

H

Hold your FlexPen with the needle pointing upwards and tap the cartridge gently a few times with your finger to make air bubbles collect at the top of the cartridge.

I

With the needle still pointing upwards, press the push-button fully. The dose selector returns to 0.

A drop of insulin should appear at the tip of the needle. If not, change the needle and repeat the procedure up to a maximum of 6 times.

If no drop of insulin appears after this, the pen is faulty and you must use a new one.

Always make sure a drop appears at the tip of the needle before injecting. This ensures that insulin is flowing. If no drop appears, no insulin will be injected, even if the dose selector moves. This may indicate that the needle is blocked or damaged.

Always check the flow before injecting. If you do not check the flow, you may receive an insufficient or even no dose of insulin. This could result in blood sugar levels that are too high.

Selecting the dose

Check that the dose selector shows 0.

J

Turn the dose selector to select the number of units you need to inject.

The dose can be corrected forwards or backwards by turning the dose selector in either direction until the correct dose is aligned with the dose marker. When turning the dose selector, be careful not to press the push-button, as insulin may leak out.

You cannot select a dose greater than the number of units remaining in the cartridge.

Before injecting insulin, always use the dose selector and dose marker to check how many units you have selected.

Do not count the clicks of the pen. If you select and inject an incorrect dose, your blood sugar level may become too high or too low. Do not use the remaining insulin scale, as it only shows the approximate amount of insulin left in the pen.

Injection

Insert the needle under the skin. Use the injection technique recommended by your doctor or nurse.

K

Inject the dose by pressing the push-button fully so that the 0 aligns with the dose marker. Be careful to press the push-button only when injecting.

Turning the dose selector will not inject insulin.

L

• Keep the push-button fully pressed and keep the needle under the skin for at least 6 seconds. This ensures that the full dose is delivered.

• Remove the needle from the skin and, once removed, release the push-button.

• Always make sure the dose selector returns to 0 after injection. If the dose selector stops before reaching 0, the full dose has not been administered, which could result in blood sugar levels that are too high.

M

Cover the needle with the large outer cap without touching it. Once the needle is covered, press the large outer cap carefully all the way on and then unscrew the needle.

Dispose of it carefully and replace the cap on the FlexPen.

Always remove the needle after each injection and store your FlexPen without a needle attached. This reduces the risk of contamination, infection, insulin leakage, blocked needles and inaccurate dosing.

Other important information

People caring for these patients must be very careful when handling used needles to reduce the risk of accidental needlestick injuries and infections.

Dispose of your used FlexPen carefully without leaving the needle attached.

Never share the pen or needles with other people. This could cause infections.

Never share the pen with other people. Your medicine could be harmful to their health.

Always keep the pen and needles out of sight and reach of other people, especially children.